Gene therapy for advanced Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests an experimental gene therapy delivered to a specific brain area to help control Parkinson's symptoms. It is for people with advanced Parkinson's whose current medications no longer work well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 40 and 70 years old
- Have had Parkinson's disease for at least 5 years
- Have advanced symptoms (Hoehn and Yahr stage 4 or 5) and significant movement problems
- Your current Parkinson's medications must work at least 30% better during a standard test
- Have not had brain surgery for Parkinson's before
- Be willing to avoid any other brain surgery for 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy that may improve movement control in people with Parkinson's disease. It involves a one-time surgical injection into the brain and requires you to be off your usual Parkinson's medications during some assessments.
This trial tests an experimental gene therapy injected directly into the brain, designed for people with Parkinson's disease who carry a specific genetic change called GBA1. The goal is to see if the treatment is safe, tolerable, and helps improve motor symptoms.
This trial tests a new gene therapy for Parkinson's disease. The therapy is delivered directly into the brain during a surgical procedure, with the goal of improving motor symptoms and reducing 'off' time.
This study tests a new cell therapy called bemdaneprocel to see if it can reduce Parkinson's symptoms and “off” time. The treatment involves transplanting special cells into the brain to help replace lost dopamine-producing cells.
This trial tests a new gene therapy delivered directly into the brain to help control Parkinson's symptoms. It is for people with advanced Parkinson's disease who still have significant movement problems despite their current medications.
This trial tests a new type of gene therapy for Parkinson's disease. It aims to make blocking cells more responsive, improving movement control and reducing symptoms.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.